AstraZeneca's Imfinzi shows positive results in early bladder cancer trial
Why we think this is neutral
The RNS announcement provides an update on the positive results from the POTOMAC Phase III trial of Imfinzi in non-muscle-invasive bladder cancer. While the results are encouraging, the announcement does not contain any of the mandatory news types that would require a more detailed analysis and sentiment scoring.
Key Points
- Imfinzi plus BCG induction and maintenance therapy showed statistically significant and clinically meaningful improvement in disease-free survival
- Safety and tolerability of Imfinzi regimen was consistent with known profiles, with no new safety concerns
- Data will be presented at a medical meeting and shared with regulatory authorities
Summary
AstraZeneca announced positive high-level results from the POTOMAC Phase III trial, which showed that one year of treatment with Imfinzi (durvalumab) plus standard-of-care Bacillus Calmette-Guérin (BCG) induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) for patients with high-risk non-muscle-invasive bladder cancer compared to BCG induction and maintenance therapy alone. The safety and tolerability of the Imfinzi regimen was consistent with the known safety profiles of the individual medicines, with no new safety concerns identified. These data will be presented at a forthcoming medical meeting and shared with global regulatory authorities.